| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 08/16/2022 | 325.53% | Barclays | $7 → $2 | Maintains | Overweight |
| 08/16/2022 | 538.3% | Raymond James | $12 → $3 | Maintains | Outperform |
| 06/01/2022 | 963.83% | BTIG | → $5 | Initiates Coverage On | → Buy |
| 04/01/2022 | 1389.36% | Barclays | $4 → $7 | Maintains | Overweight |
| 02/22/2022 | 2665.96% | Raymond James | $21 → $13 | Maintains | Outperform |
| 11/15/2021 | 4368.09% | Raymond James | $30 → $21 | Maintains | Outperform |
| 04/01/2021 | 6282.98% | Raymond James | → $30 | Initiates Coverage On | → Outperform |
| 03/09/2021 | 7346.81% | Cantor Fitzgerald | → $35 | Initiates Coverage On | → Overweight |
What is the target price for NexImmune (NEXI)?
The latest price target for NexImmune (NASDAQ: NEXI) was reported by Raymond James on November 15, 2022. The analyst firm set a price target for $0.00 expecting NEXI to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NexImmune (NEXI)?
The latest analyst rating for NexImmune (NASDAQ: NEXI) was provided by Raymond James, and NexImmune downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for NexImmune (NEXI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NexImmune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NexImmune was filed on November 15, 2022 so you should expect the next rating to be made available sometime around November 15, 2023.
Is the Analyst Rating NexImmune (NEXI) correct?
While ratings are subjective and will change, the latest NexImmune (NEXI) rating was a downgraded with a price target of $0.00 to $0.00. The current price NexImmune (NEXI) is trading at is $0.47, which is out of the analyst's predicted range.